Top

Published in:

01-01-2011 | Review Article

Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review

Authors: Akira Namera, Akihiro Nakamoto, Takeshi Saito, Masataka Nagao

Published in: Forensic Toxicology | Issue 1/2011

Abstract

A number of analogues of phenethylamine and tryptamine, which are prepared by modification of the chemical structures, are being developed for circulation on the black market. Often called “designer drugs,” they are abused in many countries, and cause serious social problems in many parts of the world. Acute deaths have been reported after overdoses of designer drugs. Various methods are required for screening and routine analysis of designer drugs in biological materials for forensic and clinical purposes. Many sample preparation and chromatographic methods for analysis of these drugs in biological materials and seized items have been published. This review presents various colorimetric detections, gas chromatographic (GC)–mass spectrometric, and liquid chromatographic (LC)–mass spectrometric methods proposed for designer drug analyses. Basic information on extractions, derivatizations, GC columns, LC columns, detection limits, and linear ranges is also summarized.

Kraemer T, Maurer HH (1998) Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. J Chromatogr B 713:163–187CrossRef

Drummer OH (1999) Chromatographic screening techniques in systematic toxicological analysis. J Chromatogr B 733:27–45CrossRef

Thevis M, Schänzer W (2007) Mass spectrometry in sports drug testing: structure characterization and analytical assays. Mass Spectrom Rev 26:79–107PubMedCrossRef

Maurer HH (2009) Mass spectrometric approaches in impaired driving toxicology. Anal Bioanal Chem 393:97–107PubMedCrossRef

Takahashi M, Nagashima M, Suzuki J, Seto T, Yasuda I, Yoshida T (2009) Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta 77:1245–1272PubMedCrossRef

Shulgin A, Shulgin A (1991) Pihkal: a chemical love story. Transform Press, Berkeley

Shulgin A, Shulgin A (1997) Tihkal: the continuation. Transform Press, Berkeley

Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH (2005) Another designer steroid: discovery, synthesis, and detection of ‘madol’ in urine. Rapid Commun Mass Spectrom 19:781–784PubMedCrossRef

Thevis M, Geyer H, Mareck U, Schänzer W (2005) Screening for unknown synthetic steroids in human urine by liquid chromatography–tandem mass spectrometry. J Mass Spectrom 40:955–962PubMedCrossRef

10.

Nielen MW, Bovee TF, van Engelen MC, Rutgers P, Hamers AR, van Rhijn JH, Hoogenboom LR (2006) Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole time-of-flight mass spectrometry identification. Anal Chem 78:424–431PubMedCrossRef

11.

De Brabander HF, Verheyden K, Mortier V, Le Bizec B, Verbeke W, Courtheyn D, Noppe H (2007) Phytosterols and anabolic agents versus designer drugs. Anal Chim Acta 586:49–56PubMedCrossRef

12.

Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Nielen MW, Panderi I, Koupparis M (2007) Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom 21:2439–2446PubMedCrossRef

13.

Vonaparti A, Lyris E, Angelis YS, Panderi I, Koupparis M, Tsantili-Kakoulidou A, Peters RJ, Nielen MW, Georgakopoulos C (2010) Preventive doping control screening analysis of prohibited substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24:1595–1609PubMedCrossRef

14.

Rothman RB, Glowa JR (1995) A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 11:1–19PubMedCrossRef

15.

Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612PubMedCrossRef

16.

Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41PubMedCrossRef

17.

Lyon RA, Glennon RA, Titeler M (1986) 3, 4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88:525–526PubMedCrossRef

18.

Rudnick G, Wall SC (1992) The molecular mechanism of “ecstasy” [3, 4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89:1817–1821PubMedCrossRef

19.

Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE (1996) Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J Med Chem 39:2953–2961PubMedCrossRef

20.

Rothman RB, Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73–88PubMedCrossRef

21.

Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18:305–313

22.

Sogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, Funada M, Kitayama S (2007) 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol Lett 170:75–82PubMedCrossRef

23.

Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH (2006) Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83:122–129PubMedCrossRef

24.

Nagai F, Nonaka R, Satoh H, Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132–137PubMedCrossRef

25.

Nakagawa T, Kaneko S (2008) Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy). J Pharmacol Sci 106:2–8PubMedCrossRef

26.

Kraemer T, Maurer HH (2002) Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24:277–289PubMedCrossRef

27.

Maurer HH, Kraemer T, Springer D, Staack RF (2004) Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 26:127–131PubMedCrossRef

28.

Staack RF, Maurer HH (2005) Metabolism of designer drugs of abuse. Curr Drug Metab 6:259–274PubMedCrossRef

29.

Meyer MR, Maurer HH (2010) Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab 11:468–482PubMedCrossRef

30.

Sitaram BR, Lockett L, Talomsin R, Blackman GL, McLeod WR (1987) In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol 36:1509–1512PubMedCrossRef

31.

Meatherall R, Sharma P (2003) Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 27:313–317PubMed

32.

Wilson JM, McGeorge F, Smolinske S, Meatherall R (2005) A foxy intoxication. Forensic Sci Int 148:31–36PubMedCrossRef

33.

Kamata T, Katagi M, Kamata HT, Miki A, Shima N, Zaitsu K, Nishikawa M, Tanaka E, Honda K, Tsuchihashi H (2006) Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab Dispos 34:281–287PubMedCrossRef

34.

Kamata T, Katagi M, Tsuchihashi H (2010) Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan. Forensic Toxicol 28:1–8CrossRef

35.

Dal Cason TA (1997) The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologs. Forensic Sci Int 87:9–53CrossRef

36.

Matsuda K, Fukuzawa T, Ishii Y, Yamada H (2007) Color reaction of 3,4-methylenedioxyamphetamines with chromotropic acid: its improvement and application to the screening of seized tablets. Forensic Toxicol 25:37–40CrossRef

37.

Nakamoto A, Namera A, Yahata M, Kuramoto T, Nishida M, Yashiki M (2007) A systematic toxicological analysis for hallucinogenic tryptamines in seized and biological materials (in Japanese with English abstract). Hiroshima Igaku Zasshi 55:1–14

38.

Uchiyama N, Kawamura M, Kamakura H, Kikura-Hanajiri R, Goda Y (2008) Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part II: color test and TLC (in Japanese with English abstract). Yakugaku Zasshi 128:981–987PubMedCrossRef

39.

Takahashi M, Nagashima M, Suzuki J, Seto T, Yasuda I, Yoshida T (2008) Analysis of phenethylamines and tryptamines in designer drugs using gas chromatography–mass spectrometry. J Health Sci 54:89–96CrossRef

40.

Kudo K, Ishida T, Hikiji W, Hayashida M, Uekusa K, Usumoto Y, Tsuji A, Ikeda N (2009) Construction of calibration-locking databases for rapid and reliable drug screening by gas chromatography-mass spectrometry. Forensic Toxicol 27:21–31CrossRef

41.

Ishida T, Kudo K, Inoue H, Tsuji A, Kojima T, Ikeda N (2006) Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography–mass spectrometry. J Anal Toxicol 30:468–477PubMed

42.

Vorce SP, Sklerov JH (2004) A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC–EI–MS and HPLC–electrospray–MS. J Anal Toxicol 28:407–410PubMed

43.

Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH (2003) Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 38:659–676PubMedCrossRef

44.

Zaitsu K, Katagi M, Kamata H, Nakanishi K, Shima N, Kamata T, Nishioka H, Miki A, Tatsuno M, Tsuchihashi H (2010) Simultaneous analysis of six novel hallucinogenic (tetrahydrobenzodifuranyl)aminoalkanes (FLYs) and (benzodifuranyl)aminoalkanes (DragonFLYs) by GC–MS, LC–MS, and LC–MS–MS. Forensic Toxicol 28:9–18CrossRef

45.

Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H (2010) Increase in split ratio enables detection of underivatized N-hydroxy-3,4-methylenedioxymethamphetamine and N-hydroxy-3,4-methylenedioxyamphetamine by capillary GC–MS. Forensic Toxicol 28:55–57CrossRef

46.

Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry. Anal Bioanal Chem 397:1225–1233PubMedCrossRef

47.

Westphal F, Rösner P, Junge T (2010) Differentiation of regioisomeric ring-substituted fluorophenethylamines with product ion spectrometry. Forensic Sci Int 194:53–59PubMedCrossRef

48.

Camilleri A, Johnston MR, Brennan M, Davis S, Caldicott DG (2010) Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci Int 197:59–66PubMedCrossRef

49.

Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH (2009) New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 44:952–964PubMedCrossRef

50.

Fujii H, Hara K, Kageura M, Kashiwagi M, Matsusue A, Kubo S (2009) High throughput chiral analysis of urinary amphetamines by GC–MS using a short narrow-bore capillary column. Forensic Toxicol 27:75–80CrossRef

51.

Rohanova M, Balikova M (2009) Studies on distribution and metabolism of p-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. Toxicology 259:61–68PubMedCrossRef

52.

Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M (2009) A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183:91–96PubMedCrossRef

53.

Archer RP (2009) Fluoromethcathinone, a new substance of abuse. Forensic Sci Int 185:10–20PubMedCrossRef

54.

Zaitsu K, Katagi M, Kamata HT, Kamata T, Shima N, Miki A, Tsuchihashi H, Mori Y (2009) Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188:131–139PubMedCrossRef

55.

Westphal F, Junge T, Rösner P, Sönnichsen F, Schuster F (2009) Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with α-pyrrolidinophenone structure. Forensic Sci Int 190:1–8PubMedCrossRef

56.

Strano-Rossi S, Botrè F, Bermejo AM, Tabernero MJ (2009) A rapid method for the extraction, enantiomeric separation and quantification of amphetamines in hair. Forensic Sci Int 193:95–100PubMedCrossRef

57.

Zaitsu K, Katagi M, Kamata HT, Miki A, Tsuchihashi H (2008) Discrimination and identification of regioisomeric β-keto analogues of 3,4-methylenedioxyamphetamines by gas chromatography–mass spectrometry. Forensic Toxicol 26:45–51CrossRef

58.

Kanai K, Takekawa K, Kumamoto T, Ishikawa T, Ohmori T (2008) Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC–MS, and GC–MS. Forensic Toxicol 26:6–12CrossRef

59.

Zaitsu K, Katagi M, Kamata H, Kamata T, Shima N, Miki A, Iwamura T, Tsuchihashi H (2008) Discrimination and identification of the six aromatic positional isomers of trimethoxyamphetamine (TMA) by gas chromatography-mass spectrometry (GC–MS). J Mass Spectrom 43:528–534PubMedCrossRef

60.

Ewald AH, Ehlers D, Maurer HH (2008) Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography–mass spectrometry. Anal Bioanal Chem 390:1837–1842PubMedCrossRef

61.

Ewald AH, Puetz M, Maurer HH (2008) Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J Chromatogr B 862:252–256CrossRef

62.

Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, Hayashi T, Kuroki H, Matoba R (2008) Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forensic Sci Int 177:77–84PubMedCrossRef

63.

Kudo K, Ishida T, Hara K, Kashimura S, Tsuji A, Ikeda N (2007) Simultaneous determination of 13 amphetamine related drugs in human whole blood using an enhanced polymer column and gas chromatography-mass spectrometry. J Chromatogr B 855:115–120CrossRef

64.

Westphal F, Junge T, Rösner P, Fritschi G, Klein B, Girreser U (2007) Mass spectral and NMR spectral data of two new designer drugs with an α-aminophenone structure: 4′-methyl-α-pyrrolidinohexanophenone and 4′-methyl-α-pyrrolidinobutyrophenone. Forensic Sci Int 169:32–42PubMedCrossRef

65.

da Costa JL, Wang AY, Micke GA, Maldaner AO, Romano RL, Martins-Júnior HA, Negrini Neto O, Tavares MF (2007) Chemical identification of 2,5-dimethoxy-4-bromoamphetamine (DOB). Forensic Sci Int 173:130–136PubMedCrossRef

66.

Kikura-Hanajiri R, Kawamura M, Saisho K, Kodama Y, Goda Y (2007) The disposition into hair of new designer drugs; methylone, MBDB and methcathinone. J Chromatogr B 855:121–126CrossRef

67.

Theobald DS, Fritschi G, Maurer HH (2007) Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-β-phenethylamine (2C-B) in rat urine using gas chromatography–mass spectrometry. J Chromatogr B 846:374–377CrossRef

68.

Ewald AH, Fritschi G, Maurer HH (2007) Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography–mass spectrometry. J Chromatogr B 857:170–174CrossRef

69.

Yahata M, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (2006) In-matrix derivatization and automated headspace solid-phase microextraction for GC–MS determination of amphetamine-related drugs in human hair. Forensic Toxicol 24:51–57CrossRef

70.

Theobald DS, Maurer HH (2006) Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-β-phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 41:1509–1519PubMedCrossRef

71.

Theobald DS, Pütz M, Schneider E, Maurer HH (2006) New designer drug 4-iodo-2,5-dimethoxy-β-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom 41:872–886PubMedCrossRef

72.

Theobald DS, Maurer HH (2006) Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-β-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J Chromatogr B 842:76–90CrossRef

73.

Rösner P, Quednow B, Girreser U, Junge T (2005) Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). Forensic Sci Int 148:143–156PubMedCrossRef

74.

Klette KL, Jamerson MH, Morris-Kukoski CL, Kettle AR, Snyder JJ (2005) Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by fast gas chromatography–mass spectrometry. J Anal Toxicol 29:669–674PubMed

75.

Han E, Yang W, Lee J, Park Y, Kim E, Lim M, Chung H (2005) The prevalence of MDMA/MDA in both hair and urine in drug users. Forensic Sci Int 152:73–77PubMedCrossRef

76.

Peters FT, Meyer MR, Fritschi G, Maurer HH (2005) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography–mass spectrometry. J Chromatogr B 824:81–91CrossRef

77.

Ewald AH, Peters FT, Weise M, Maurer HH (2005) Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography–mass spectrometry. J Chromatogr B 824:123–131CrossRef

78.

Carmo H, de Boer D, Remião F, Carvalho F, dos Reys LA, de Lourdes Bastos M (2004) Metabolism of the designer drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J Chromatogr B 811:143–152

79.

Staack RF, Fehn J, Maurer HH (2003) New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography–mass spectrometry. J Chromatogr B 789:27–41CrossRef

80.

Springer D, Peters FT, Fritschi G, Maurer HH (2003) New designer drug 4′-methyl-α-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography–mass spectrometry. J Chromatogr B 789:79–91CrossRef

81.

Springer D, Fritschi G, Maurer HH (2003) Metabolism and toxicological detection of the new designer drug 4′-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography–mass spectrometry. J Chromatogr B 793:331–342CrossRef

82.

Springer D, Fritschi G, Maurer HH (2003) Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography–mass spectrometry. J Chromatogr B 793:377–388CrossRef

83.

Springer D, Fritschi G, Maurer HH (2003) Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4’-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 796:253–266CrossRef

84.

Musshoff F, Lachenmeier DW, Kroener L, Madea B (2002) Automated headspace solid-phase dynamic extraction for the determination of amphetamines and synthetic designer drugs in hair samples. J Chromatogr A 958:231–238PubMedCrossRef

85.

Springer D, Peters FT, Fritschi G, Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography–mass spectrometry. J Chromatogr B 773:25–33CrossRef

86.

Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’). Toxicol Lett 112–113:133–142PubMedCrossRef

87.

Ensslin HK, Kovar KA, Maurer HH (1996) Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, “Eve”) and its metabolites in urine by gas chromatography–mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B 683:189–197CrossRef

88.

Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (2007) Identification and quantitative determination of 5-methoxy-N,N-di-n-propyltryptamine in urine by isotope dilution gas chromatography–mass spectrometry. Forensic Toxicol 25:1–7CrossRef

89.

Itokawa M, Iwata K, Takahashi M, Sugihara G, Sasaki T, Abe Y, Uno M, Hobo M, Jitoku D, Inoue K, Arai M, Yasuda I, Shintani M (2007) Acute confusional state after designer tryptamine abuse. Psychiatry Clin Neurosci 61:196–199PubMedCrossRef

90.

Westphal F, Junge T, Girreser U, Stobbe S, Pérez SB (2009) Structure elucidation of a new designer benzylpiperazine: 4-bromo-2,5-dimethoxybenzylpiperazine. Forensic Sci Int 187:87–96PubMedCrossRef

91.

Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nishikawa M, Nakajima K, Tsuchihashi H (2005) Development of simultaneous gas chromatography–mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J Chromatogr B 819:315–322CrossRef

92.

Staack RF, Maurer HH (2003) Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC–MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol 27:560–568PubMed

93.

Staack RF, Maurer HH (2003) Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J Chromatogr B 798:333–342CrossRef

94.

Staack RF, Fritschi G, Maurer HH (2002) Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography–mass spectrometry. J Chromatogr B 773:35–46CrossRef

95.

de Boer D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ, Maes RA (2001) Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 121:47–56PubMedCrossRef

96.

Sato S, Suzuki S, Lee XP, Sato K (2010) Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and related compounds VII. Quantification of α-methylfentanyl metabolites excreted in rat urine. Forensic Sci Int 195:68–72PubMedCrossRef

97.

Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH (2008) New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 43:305–316PubMedCrossRef

98.

Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH (2008) Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci Int 181:47–51PubMedCrossRef

99.

Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH (2008) Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography–mass spectrometry. J Chromatogr A 1186:380–390PubMedCrossRef

100.

Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (2010) Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31–38PubMedCrossRef

101.

Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRef

102.

Wohlfarth A, Weinmann W, Dresen S (2010) LC–MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal Bioanal Chem 396:2403–2414PubMedCrossRef

103.

Pichini S, Pujadas M, Marchei E, Pellegrini M, Fiz J, Pacifici R, Zuccaro P, Farré M, de la Torre R (2008) Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of “hallucinogenic designer drugs” in urine of consumers. J Pharm Biomed Anal 47:335–342PubMedCrossRef

104.

Concheiro M, de Castro A, Quintela O, López-Rivadulla M, Cruz A (2006) Determination of drugs of abuse and their metabolites in human plasma by liquid chromatography-mass spectrometry. An application to 156 road fatalities. J Chromatogr B 832:81–89CrossRef

105.

Kikura-Hanajiri R, Kawamura M, Miyajima A, Sunouchi M, Goda Y (2010) Determination of a new designer drug, N-hydroxy-3,4-methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography–tandem mass spectrometry. Forensic Sci Int 198:62–69PubMedCrossRef

106.

Nieddu M, Boatto G, Pirisi MA, Baralla E (2009) Multi-residue analysis of eight thioamphetamine designer drugs in human urine by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 23:3051–3056PubMedCrossRef

107.

Tabernero MJ, Felli ML, Bermejo AM, Chiarotti M (2009) Determination of ketamine and amphetamines in hair by LC/MS/MS. Anal Bioanal Chem 395:2547–2557PubMedCrossRef

108.

Shima N, Katagi M, Kamata H, Zaitsu K, Kamata T, Miki A, Tsuchihashi H, Sakuma T, Nemoto N (2008) Conjugates of p-hydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine in blood obtained from methamphetamine and 3,4-methylenedioxymethamphetamine users: analysis by LC–MS–MS. Forensic Toxicol 26:58–65CrossRef

109.

Nieddu M, Boatto G, Pirisi MA, Azara E, Marchetti M (2008) LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples. J Chromatogr B 867:126–130CrossRef

110.

Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N (2007) Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine. J Chromatogr B 857:123–129CrossRef

111.

Kłys M, Rojek S, Woźniak K, Rzepecka-Woźniak E (2007) Fatality due to the use of a designer drug MDMA (Ecstasy). Legal Med 9:185–191PubMedCrossRef

112.

Bogusz MJ, Krüger KD, Maier RD (2000) Analysis of underivatized amphetamines and related phenethylamines with high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Anal Toxicol 24:77–84PubMed

113.

Vorce SP, Holler JM, Levine B, Past MR (2008) Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC–MS and LC–ESI–MS. J Anal Toxicol 32:444–450PubMed

114.

Ojanperä I, Gergov M, Liiv M, Riikoja A, Vuori E (2008) An epidemic of fatal 3-methylfentanyl poisoning in Estonia. Int J Legal Med 122:395–400PubMedCrossRef

115.

Reepmeyer JC, Woodruff JT (2006) Use of liquid chromatography-mass spectrometry and a hydrolytic technique for the detection and structure elucidation of a novel synthetic vardenafil designer drug added illegally to a “natural” herbal dietary supplement. J Chromatogr A 1125:67–75PubMedCrossRef

116.

McDowall RD (1989) Sample preparation for biomedical analysis. J Chromatogr 492:3–58PubMedCrossRef

117.

Zhang N, Hoffman KL, Li W, Rossi DT (2000) Semi-automated 96-well liquid–liquid extraction for quantitation of drugs in biological fluids. J Pharm Biomed Anal 22:131–138PubMedCrossRef

118.

Hennion MC (1999) Solid-phase extraction: method development, sorbents, and coupling with liquid chromatography. J Chromatogr A 856:3–54PubMedCrossRef

119.

Kamata T, Nishikawa M, Katagi M, Tsuchihashi H (2006) Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user. Forensic Toxicol 24:36–40CrossRef

120.

Grieshaber AF, Moore KA, Levine B (2001) The detection of psilocin in human urine. J Forensic Sci 46:627–630PubMed

121.

Kamata T, Nishikawa M, Katagi M, Tsuchihashi H (2003) Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. J Chromatogr B 796:421–427CrossRef

122.

Inoue T, Suzuki S, Niwaguchi T (1983) Stability of perfluoroacyl derivatives of methamphetamine and its metabolites (in Japanese with English abstract). Eisei Kagaku 29:412–417

123.

Delbeke FT, Debackere M, Jonckheere JA, De Leenheer AP (1983) Pentafluorobenzoyl derivatives of doping agents: I. Extractive benzoylation and gas chromatography with electron-capture detection of primary and secondary amines. J Chromatogr 273:141–149PubMedCrossRef

124.

Husek P (1991) Rapid derivatization and gas chromatographic determination of amino acids. J Chromatogr A 552:289–299CrossRef

125.

Meatherall R (1995) Rapid GC–MS confirmation of urinary amphetamine and methamphetamine as their propylchloroformate derivatives. J Anal Toxicol 19:316–322PubMed

126.

Birkmayer W, Riederer P, Youdim MB (1982) (−)Deprenyl in the treatment of Parkinson’s disease. Clin Neuropharmacol 5:195–230PubMedCrossRef

127.

Tarjányi Z, Kalász H, Szebeni G, Hollósi I, Báthori M, Fürst S (1998) Gas-chromatographic study on the stereoselectivity of deprenyl metabolism. J Pharm Biomed Anal 17:725–731PubMedCrossRef

128.

Pharmaceutical Society of Japan (ed) (2006) Standard methods of chemical analysis in poisoning with commentary, 2006—analysis, toxicity and treatment (in Japanese). Tokyo Kagaku Dojin, Tokyo

Title: Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review
Authors: Akira Namera
Akihiro Nakamoto
Takeshi Saito
Masataka Nagao
Publication date: 01-01-2011
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 1/2011
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-010-0107-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Detection of saxitoxin in counterterrorism using a commercial lateral flow immunoassay kit

Urinary morphine and codeine concentrations after ingestion of bean-jam buns decorated with poppy seeds

8-Hydroxy-2′-deoxyguanosine and arsenic compounds in urine and serum of a 4-year-old child suffering from acute promyelocytic leukemia during treatment with arsenic trioxide

Optimization of simultaneous analysis of tetrodotoxin, 4-epitetrodotoxin, 4,9-anhydrotetrodotoxin, and 5,6,11-trideoxytetrodotoxin by hydrophilic interaction liquid chromatography–tandem mass spectrometry

Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the Internet

Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products